Trial reportThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2008
Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.
Trial report in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 57 citations in OpenAlex.
- Racial and Ethnic Reporting and Representation in US Alzheimer Clinical Trials: A Systematic Review.JAMA network open · 2026Pooled it
- Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia.The Cochrane database of systematic reviews · 2020Pooled it
- Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.The Cochrane database of systematic reviews · 2012Pooled it
- High‑fat diet and cognitive dysfunction: Mechanistic insights into diet‑induced neurodegeneration (Review).International journal of molecular medicine · 2026Review
- Childhood insulin resistance and neural stem cell dysfunction in psychiatric disorders: Role ofWorld journal of stem cells · 2025Review
- Mechanisms to medicines: navigating drug repurposing strategies in Alzheimer's disease.Frontiers in aging neuroscience · 2025Review
- Aging and Alzheimer's: the critical role of mitochondrial dysfunction and synaptic alterations.Frontiers in synaptic neuroscience · 2025Review
- The selective cyclooxygenase-2 inhibitor NS398 ameliorates cisplatin-induced impairments in mitochondrial and cognitive function.Frontiers in molecular neuroscience · 2023Article
- Antiplatelets and Vascular Dementia: A Systematic Review.Journal of aging research · 2022Review
- Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimer's Disease.International journal of molecular sciences · 2021Review
- Down-regulation of cyclin D2 in amyloid β toxicity, inflammation, and Alzheimer's disease.PloS one · 2021Article
- Alterations of Transcription of Genes Coding Anti-oxidative and Mitochondria-Related Proteins in Amyloid β Toxicity: Relevance to Alzheimer's Disease.Molecular neurobiology · 2020Article
- A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease.Frontiers in immunology · 2020Review
- Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.European journal of nuclear medicine and molecular imaging · 2019Article
- Nonsteroidal anti-inflammatory drug, indomethacin improves spatial memory and NMDA receptor function in aged animals.Neurobiology of aging · 2018Article
- Cognitive Impairment in Chronic Obstructive Pulmonary Disease (COPD): Possible Utility of Marine Bioactive Compounds.Marine drugs · 2018Review
- Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach.Computational and structural biotechnology journal · 2017Article
- Indomethacin Increases Neurogenesis across Age Groups and Improves Delayed Probe Trial Difference Scores in Middle-Aged Rats.Frontiers in aging neuroscience · 2017Article
- Cytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimer's Disease.Journal of clinical & cellular immunology · 2016Article
- The Lipoxygenases: Their Regulation and Implication in Alzheimer's Disease.Neurochemical research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveBecause anti-inflammatory drugs may delay cognitive decline and influence brain metabolism in normal aging, the authors determined the effects of the cyclooxygenase-2 inhibitor, celecoxib, on cognitive performance and regional cerebral glucose metabolism in nondemented volunteers with mild age-related memory decline.
designRandomized, double-blind, placebo-controlled, parallel group trial with 18-months of exposure to study medication.
settingUniversity research institute.
participantsEighty-eight subjects, aged 40-81 years (mean: 58.7, SD: 8.9 years) with mild self-reported memory complaints but normal memory performance scores were recruited from community physician referrals, media coverage, and advertising. Forty subjects completed the study.
interventionsDaily celecoxib dose of 200 or 400 mg, or placebo.
main outcome measuresStandardized neuropsychological test battery and statistical parametric mapping (SPM) of FDG-PET scans performed during mental rest.
resultsMeasures of cognition showed significant between-group differences in executive functioning (F [1, 30] = 5.06, p = 0.03) and language/semantic memory (F [1, 31] = 6.19, p = 0.02), favoring the celecoxib group compared with the placebo group. Concomitantly, FDG-PET scans demonstrated bilateral metabolic increases in prefrontal cortex in the celecoxib group in the vicinity of Brodmann's areas 9 and 10, but not in the placebo group. SPM analyses of the PET data pooled by treatment arm corresponded to a 6% increase in activity over pretreatment levels (p <0.01, after adjustment for multiple comparisons).
conclusionsThese results suggest that daily celecoxib use may improve cognitive performance and increase regional brain metabolism in people with age-associated memory decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.